GLP-1 weight loss drugs are increasingly popular as a treatment for obesity. But a lot of employer-sponsored health plans won ...

The FDA’s approval of Wegovy on June 4, 2021, ended a seven-year drought in new obesity treatments and set off a chain reaction that has reshaped how doctors, patients, and insurers think about excess ...

In this first episode of a three-part Business Daily series on the global weight-loss economy, Sam Fenwick examines the real ...

KwikPen® for single-patient use available from Lilly at $449 across all doses through the Lilly Employer Connect platform, with reduced cost-share ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

Half advice show. Half survival guide. Half absurdity-fest. (Wait, how does this work again? We're not numbers people.) Each episode, we answer all your burning questions, from how to survive a public ...

Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction ...

In Focus delivers deeper coverage of the political, cultural, and ideological issues shaping America. Published daily by senior writers and experts, these in-depth pieces go beyond the headlines to ...

In recent years, GLP-1 medications have become one of the most talked-about treatments for weight loss and metabolic health. Originally developed to manage type 2 diabetes, these medicines are now ...

Eli Lilly and Company today announced the launch of its Employer Connect platform, introducing new options to help close the access gap in U.S. obesity care. Lilly's platform expands choice, ...

The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce the tragic outcomes they cause, a large new study ...